CRP and non-small cell lung carcinoma: In the observational study (cohort #1), the largest and most geographically heterogeneous to our knowledge, we demonstrate that elevated pretreatment CRP defines a subset of patients with NSCLC with poorer outcomes from ICI-based therapies.